Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 31M | 34M | 33M | 36M | 30M |
| Gross Profit | 18M | 19M | 18M | 22M | 20M |
| Operating Income | -6M | -9M | -9M | -5M | -4M |
| EBITDA | -1M | -3M | -3M | 1M | 2M |
| Net Income | -6M | -10M | -11M | -6M | -3M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.14
+0.00% today
1Y Change
-93.99%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
STRATA Skin Sciences, Inc. (SSKN) is a Healthcare stock with listed on OTC. The stock last traded around $0.14 and down 94.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -8.5%, EPS growth of -419.2%, a dividend yield of 0.0%. What stands out right now is revenue -8.5%, EPS -419.2%, free cash flow -194.3% with operating margin -19.7% and ROIC -31.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SSKN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SSKN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SSKN Max Drawdown
-95.76%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SSKN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$30.0M
-17.1% YoY
FY Net Income
-$2.7M
+51.2% YoY
Free Cash Flow
-$2.1M
+54.0% YoY
Revenue Growth
-8.5%
EPS Growth
-419.2%
Gross Margin
57.8%
Net Margin
-21.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 31M | 34M | 33M | 36M | 30M |
| Gross Profit | 18M | 19M | 18M | 22M | 20M |
| Operating Income | -6M | -9M | -9M | -5M | -4M |
| EBITDA | -1M | -3M | -3M | 1M | 2M |
| Net Income | -6M | -10M | -11M | -6M | -3M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 8M | 7M | 7M | 5M | 13M |
| Total Assets | 31M | 36M | 42M | 52M | 47M |
| Total Liabilities | 28M | 31M | 29M | 30M | 21M |
| Shareholder Equity | 3M | 5M | 13M | 22M | 25M |
| Total Debt | 16M | 16M | 16M | 8M | 8M |
| Net Debt | 8M | 9M | 9M | 3M | -5M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
+236.1% YoY
Capital Expenditures
4M
-2.8% YoY
Free Cash Flow
2M
+54.0% YoY
Key ratios
Gross Margin
57.8%
Operating Margin
-19.7%
Net Margin
-21.1%
ROE
-360.3%
Debt / Equity
5.59x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.